Lexeo Therapeutics, Inc. Common Stock (LXEO)
Healthcare
Biotechnology
—
4.10 $
-5.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Lexeo Therapeutics, Inc. Common Stock (LXEO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -99 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -3.1 | -44 | -55 | -59 | -81 | -99 | |
| 0.0 | 0.0 | 1.1 | 1.8 | 2.0 | 0.4 | |
| 0.0 | 0.4 | 1.8 | 3.0 | 12 | 12 | |
| 0.2 | 6.0 | 1.8 | 1.5 | 2.7 | -9.5 | |
| 0.0 | 0.2 | 0.9 | 0.2 | 0.5 | 0.4 | |
| – | -0.2 | -0.9 | -0.2 | -94 | -90 | |
| – | – | – | 0.0 | 0.0 | 80 | |
| – | 0.0 | -0.2 | 3.6 | -0.4 | -0.5 | |
| 32 | 151 | 0.2 | 104 | 89 | 217 | |
| 29 | 106 | -55 | 44 | -86 | 28 | |
| -3.1 | -44 | -55 | -60 | -82 | -99 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.